Clinical trial · Observational
Collection of Blood From Patients With Cancer
Biospecimen Acquisition From Human Subjects
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Healthy Volunteers
- description
- Healthy volunteers 18 years of age and older
- label
- Participants
- description
- Participants with cancer 18 years of age and older
Primary outcomes (3)
- measure
- Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis.
- timeFrame
- ongoing
- description
- Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis.
- measure
- Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes.
- timeFrame
- ongoing
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
* INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. Ability to understand and the willingness to sign a written informed consent document. INCLUSION FOR APHERESIS: Note: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference. Hemoglobin greater than or equal to 10 mg/dL and platelet count \> 75,000/mm(3) Weight greater than 25 kg HIV negative Prothrombin Time - within normal limits Partial Thromboplastin Time - within normal limits Medically indicated central line in place or adequate peripheral venous access EXCLUSION CRITERIA: None.
References
Publications (0)
Data not yet available